HCPCS Level II · Drugs administered other than oral method
J3404Injection, zopapogene imadenovec-drba suspension, per therapeutic dose
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J3404
J3404 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, zopapogene imadenovec-drba suspension, per therapeutic dose.
It was added to HCPCS effective 04/01/2026.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj zopapogene per ther dose
- Date added
- 04/01/2026
- Action effective
- 04/01/2026
- BETOS
- O1E
Related J34xx codes
- J3401Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml
- J3402Injection, remestemcel-l-rknd, per therapeutic dose
- J3403Revakinagene taroretcel-lwey, per implant
- J3405Injection, onasemnogene abeparvovec-brve, per treatment
- J3406Injection, omidubicel-onlv, per therapeutic dose
- J3410Injection, hydroxyzine hcl, up to 25 mg
- J3411Injection, thiamine hcl, 100 mg
- J3415Injection, pyridoxine hcl, 100 mg
- J3420Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
- J3424Injection, hydroxocobalamin, intravenous, 25 mg
- J3425Injection, hydroxocobalamin, intramuscular, 10 mcg
- J3430Injection, phytonadione (vitamin k), per 1 mg
Common questions about J3404
Is HCPCS J3404 still valid?
- Yes. J3404 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J3404?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.